Physician profile
Michael Fine
NPI 1346670007
$360,381.04
in general payments reported to CMS, 2019-2025
57 companies · $30K in 2025
The $30K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85K · 2020: $31K · 2021: $67K · 2022: $71K · 2023: $33K · 2024: $43K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $88K · Honoraria: $6,700 · Travel and Lodging: $6,434 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,875 · Food and Beverage: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $87,529.58 |
| Honoraria | $6,700.00 |
| Travel and Lodging | $6,434.39 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,875.00 |
| Food and Beverage | $227.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $45,542.21 | 2019-2023 | Dupixent |
| Genzyme Corporation | $30,941.65 | 2019-2024 | |
| Glaxosmithkline, LLC. | $23,667.50 | 2020-2025 | |
| Pfizer INC. | $18,065.22 | 2019-2024 | |
| Vertex Pharmaceuticals Incorporated | $14,880.00 | 2020-2023 | |
| Amgen INC. | $13,100.00 | 2021-2024 | Lumakras |
| Otsuka America Pharmaceutical, INC. | $10,700.00 | 2020-2022 | |
| Sanofi Pasteur INC. | $10,568.00 | 2020-2024 | |
| Pacira Pharmaceuticals Incorporated | $10,487.95 | 2025 | Zilretta, Exparel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10,433.02 | 2023-2025 | Jardiance |
| Leo Pharma INC. | $8,641.31 | 2019-2022 | |
| Eisai INC. | $7,930.00 | 2019-2023 | |
| Biomarin Pharmaceutical INC. | $7,882.95 | 2022-2024 | Voxzogo 1.2mg |
| Ucb, INC. | $7,706.52 | 2019 | |
| Abbott Laboratories | $6,892.41 | 2025 | Afinion 2, Alere Cholestech Ldx |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Fine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.